Redasemtide trifluoroacetate is under clinical development by Shionogi and currently in Phase II for Dilated Cardiomyopathy. According to GlobalData, Phase II drugs for Dilated Cardiomyopathy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Redasemtide trifluoroacetate LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Redasemtide trifluoroacetate overview
Redasemtide trifluoroacetate is under development for the treatment of acute ischemic stroke, cardiomyopathy, chronic liver disease, liver cirrhosis, non-alcoholic steatohepatitis, hepatitis B, hepatitis C, epidermolysis bullosa, knee osteoarthritis, and dilated, ischemic cardiomyopathy. The drug candidate is administered through intravenous drip route. It acts by targeting high mobility group protein B1 (HMGB 1) and protein S100 A8.
Shionogi overview
Shionogi focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for therapeutic areas including metabolic disorders, pain/central nervous system (CNS), infectious diseases and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan, North America and Europe. Shionogi is headquartered in Osaka, Japan.
For a complete picture of Redasemtide trifluoroacetate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
